ResMed Inc. Announces Record Financial Results for the Quarter Ended Septembe...(rtization of acquired intangible assets ...),Health

Date:11/5/2009

rtization of acquired intangible assets 1,845 1,933 Donation to Foundation 1,000 - ---------------------- ----- --- Total operating expenses 97,515 90,563 ------------------------ ------ ------ Income from operations 52,663 36,564 ---------------------- ------ ------ Other income (expense), net: Interest income (expense), net 2,125 3,231 Other, net 3,118 (1,068) ---------- ----- ------ Total other income (expense), net 5,243 2,163 --------------------------------- ----- ----- Income before income taxes 57,906 38,727 Income taxes 15,804 10,701 ------------ ------ ------ Net income $42,102 $28,026 ---------- ------- ------- Basic earnings per share $0.56 $0.37 Diluted earnings per share $0.55 $0.36 Basic shares outstanding 75,394 75,613 Diluted shares outstanding 76,762 77,180 -------------------------- ------ ------

                       RESMED INC AND SUBSIDIARIES
                 Consolidated Balance Sheets (Unaudited)
            (In US$ thousands except share and per share data)


                                                September 30,  June 30,
                                                    2009         2009
                                                    ----         ----
    Assets
    Current assets
'/>"/>
SOURCE  ResMed Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 
Related medicine technology :

1. ResMed Acquires Laboratoires Narval
2. Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert
3. Bionovo Announces Third Quarter 2009 Highlights and Financial Results
4. Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results
5. OTCBB-VHGI Announces LOI to Sell Certain Assets for $10 Million Cash/Stock to WNDM; With Stock Dividend to be Distributed to Shareholders in 2010
6. Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
7. Reminder Webcast Alert: Transgenomic, Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
8. GSI Group Inc. Announces NASDAQ Delisting and Reports Progress on Revenue Recognition Review and Preliminary Third Quarter 2009 Bookings and Cash Balance
9. Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference
10. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
11. InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF